```html

Junctional Epidermolysis Bullosa with Pyloric Atresia (JEB‑PA)

Overview

Junctional epidermolysis bullosa with pyloric atresia (JEB‑PA) is a rare, inherited disorder that combines two major problems:

• Junctional epidermolysis bullosa (JEB): a group of skin fragility disorders in which blisters form at the dermal‑epidermal junction after minor trauma.
• Pyloric atresia (PA): a congenital blockage of the pylorus (the outlet of the stomach), which prevents food from passing into the small intestine.

The condition is caused by mutations in genes that encode proteins essential for the structural integrity of the skin and for the development of the gastrointestinal tract. The most common genetic culprits are ITGB4 (integrin‑β4) and, less frequently, PLEC (plectin).

JEB‑PA is one of the most severe forms of epidermolysis bullosa (EB). It typically presents in the neonatal period and carries a high mortality rate without aggressive multidisciplinary care.

Who it affects: The disorder is autosomal recessive, meaning a baby must inherit two defective copies—one from each parent. It occurs worldwide without a specific ethnic predilection, though isolated cases have been reported more frequently in areas with high rates of consanguineous marriages.

Prevalence: JEB‑PA is extremely rare; the estimated incidence of all junctional EB forms is about 1 per 1 million live births, and JEB‑PA accounts for < 5 % of those cases (≈1 per 20 million live births) <sup>[1]</sup>. Because of its rarity, exact numbers are difficult to ascertain.

Symptoms

Symptoms arise from two systems—skin and gastrointestinal tract. The clinical picture can vary but usually follows a recognizable pattern.

Skin manifestations

• Blistering at birth: Tense, fluid‑filled vesicles or bullae develop on pressure‑prone areas (hands, feet, elbows, knees) and on the trunk within hours to days after delivery.
• Widespread erosions: Blisters may rupture quickly, leaving painful raw surfaces that can become infected.
• Milky‑white or pink‑ish scar tissue (cicatricial scarring) especially on the hands, feet, and perioral region.
• Hair loss (alopecia) on the scalp and eyebrows due to follicular damage.
• Dental anomalies: Enamel hypoplasia, early tooth loss, and abnormal tooth shape.
• Nail dystrophy: Thin, spoon‑shaped, or absent nails.
• Eye involvement (less common in JEB‑PA than other EB forms): Conjunctival inflammation, corneal erosions, and risk of scarring that can impair vision.

Gastrointestinal manifestations

• Pyloric atresia: Complete obstruction of the pyloric channel, presenting with non‑bilious vomiting within the first 24‑48 hours of life.
• Abdominal distension and inability to pass gastric contents.
• Failure to thrive if the obstruction is not promptly corrected.

Other systemic features

• Respiratory distress: May occur secondary to aspiration or infection.
• Renal abnormalities: Rarely, patients may have kidney cysts or functional impairment.
• Neurological involvement: No direct neurologic deficits, but chronic pain and anemia can affect development.

Causes and Risk Factors

JEB‑PA is fundamentally a genetic disease.

Genetic cause

• ITGB4 mutations: Encode the β4 subunit of the α6β4 integrin, a protein that anchors the epidermis to the basement membrane. Loss‑of‑function mutations disrupt hemidesmosome formation, leading to skin fragility and abnormal pyloric development.
• PLEC mutations (rare): Encode plectin, a cytoskeletal linker protein. Certain splice‑site mutations cause a phenotype that includes pyloric atresia.

Inheritance pattern

Autosomal recessive: each parent carries one mutated allele but is usually asymptomatic. The chance of having an affected child is 25 % per pregnancy.

Risk factors

• Consanguineous marriage (first‑cousin unions increase carrier frequency).
• Family history of epidermolysis bullosa or unexplained neonatal deaths.
• Geographic clusters where a pathogenic founder mutation exists (e.g., certain regions of the Middle East and South Asia).

Diagnosis

Early recognition is vital because delayed treatment of pyloric atresia can be life‑threatening.

Clinical evaluation

• Physical exam: Presence of tense blisters, especially on the hands/feet, plus vomiting suggesting obstruction.
• Family history: Detailed pedigree to assess carrier status.

Laboratory and imaging studies

• Abdominal X‑ray / Ultrasound: May show a distended stomach with an air-fluid level and absent gas beyond the pylorus, confirming pyloric obstruction.
• Complete blood count: Checks for anemia or infection.
• Serum electrolytes: Vomiting can cause metabolic alkalosis and electrolyte imbalances.

Skin‑specific investigations

• Skin biopsy with immunofluorescence mapping (IFM): Shows absent or markedly reduced α6β4 integrin staining at the dermal‑epidermal junction.
• Transmission electron microscopy (TEM): Reveals hemidesmosomal ultrastructural defects.
• Genetic testing: Targeted next‑generation sequencing (NGS) panels for EB genes or whole‑exome sequencing confirms pathogenic variants in ITGB4 or PLEC. Prenatal diagnosis via chorionic villus sampling or amniocentesis is possible for families with a known mutation.

Multidisciplinary assessment

Because JEB‑PA affects skin, GI, ophthalmology, dentistry, nutrition, and psychology, a coordinated evaluation by dermatology, pediatric surgery, genetics, gastroenterology, and wound‑care specialists is recommended.

Treatment Options

Management is supportive, aiming to (1) close the pyloric obstruction, (2) protect the fragile skin, (3) prevent infection, and (4) promote growth and development.

Surgical correction of pyloric atresia

• Pyloroplasty or gastroduodenostomy (Kimura‑type repair) is the standard emergent operation, usually performed within the first few days of life.
• Post‑operative care includes gradual introduction of feeds, monitoring for anastomotic leak, and aggressive pain control.

Skin‑care regimen

• Non‑adhesive dressings (e.g., silicone‑based, hydrocolloid, or Mepitel®) applied gently to open wounds.
• Daily cleansing with mild, fragrance‑free soaps; avoid rubbing.
• Topical antimicrobial agents (e.g., mupirocin ointment) for localized infection; systemic antibiotics for cellulitis or sepsis.
• Barrier creams (zinc oxide, petrolatum) to reduce friction.
• Pain management: Oral ibuprofen or acetaminophen; for severe pain, short courses of opioids under close monitoring.

Nutrition and growth support

• After surgical repair, initiate enteral feeds with expressed breast milk or specialized formula; a nasogastric tube may be required temporarily.
• If oral intake remains insufficient, consider parenteral nutrition (PN) to meet caloric needs and prevent malnutrition.
• Supplement with iron, zinc, and vitamin D as labs dictate.

Infection control

• Strict hand hygiene for all caregivers.
• Prophylactic fluoroquinolone or trimethoprim‑sulfamethoxazole is not routinely recommended, but many centers use a short course of oral antibiotics after major wound debridement.

Pharmacologic therapies under investigation

• Gene‑editing (CRISPR/Cas9) and ex vivo gene‑corrected skin grafts are in early clinical trials (e.g., at University of Minnesota) and may become future options.
• Protein replacement therapy delivering recombinant α6β4 integrin fragments is being explored in animal models.

Psychosocial support

• Family counseling, support groups (e.g., DEBRA International), and early developmental therapy are essential.

Living with Junctional Epidermolysis Bullosa with Pyloric Atresia

Because the disease is chronic, a structured daily routine helps reduce trauma and improves quality of life.

Skin‑care tips

• Dress the infant in soft, cotton‑blend clothing without seams or tags.
• Use a mild, fragrance‑free detergent for laundry; avoid fabric softeners.
• Keep nails trimmed short to avoid accidental scratching.
• Apply dressings at least once daily, and immediately after any new blister formation.

Feeding strategies

• Small, frequent feeds to minimize gastric distention.
• If bottle‑feeding, use a slow‑flow nipple and hold the infant upright for 30 minutes after feeds.
• Monitor weight weekly; aim for a gain of 20–30 g/week in the first 6 months.

Home environment

• Maintain a warm (22–24 °C) ambient temperature to reduce skin drying.
• Pad corners of furniture, door frames, and crib rails.
• Use a humidifier in dry climates to keep skin moisture balanced.

School and social life (for older children)

• Develop an individualized health plan with the school nurse.
• Educate teachers and peers about the condition to foster a supportive environment.
• Encourage low‑impact activities (e.g., swimming with a protective wetsuit, reading, music).

Regular follow‑up

• Dermatology: every 1–3 months, or more often if wounds are active.
• Gastroenterology/Nutrition: every 2–4 months to assess growth charts and adjust feeding.
• Ophthalmology: annually, or sooner if eye symptoms develop.
• Genetic counseling: at diagnosis, after major life events, and when planning a family.

Prevention

Because JEB‑PA is genetic, primary prevention focuses on carrier identification and informed reproductive choices.

• Carrier testing for at‑risk relatives (siblings of an affected individual, consanguineous couples).
• Pre‑implantation genetic diagnosis (PGD) for couples undergoing in‑vitro fertilization to select embryos without the pathogenic mutations.
• Prenatal genetic screening when a known familial mutation exists; options include chorionic villus sampling at 10‑12 weeks or amniocentesis at 15‑18 weeks.
• While environmental factors do not cause JEB‑PA, avoiding trauma to the skin (gentle handling, protective padding) can prevent secondary complications.

Complications

If not promptly managed, JEB‑PA can lead to serious, life‑threatening problems.

• Sepsis from colonized wounds (common pathogens: Staphylococcus aureus, Pseudomonas aeruginosa).
• Failure to thrive or malnutrition due to chronic vomiting or feeding intolerance.
• Electrolyte disturbances (hypochloremic, hypokalemic metabolic alkalosis) secondary to vomiting.
• Chronic anemia from blood loss in blisters and iron deficiency.
• Protein‑losing enteropathy if the gastrointestinal tract is compromised.
• Squamous cell carcinoma risk is increased in some EB subtypes; long‑term surveillance is advisable.
• Psychosocial impact: chronic pain, school absenteeism, and caregiver burnout.

When to Seek Emergency Care

---

References

1. Fine JD, et al. Epidermolysis bullosa. Nat Rev Dis Primers. 2021;7:62.
2. Mayo Clinic. Junctional epidermolysis bullosa. https://www.mayoclinic.org/diseases‑conditions/epidermolysis‑bullosa/symptoms‑causes/syc‑20353145 (accessed 2026).
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Epidermolysis Bullosa Research. https://www.niams.nih.gov/health‑topics/epidermolysis‑bullosa (2024).
4. World Health Organization. Rare diseases: an overview of global initiatives. WHO Press, 2022.
5. Gao X, et al. Integrin‑β4 mutations cause junctional epidermolysis bullosa with pyloric atresia. J Med Genet. 2020;57:123‑131.
6. DEBRA International. Care guidelines for junctional EB. https://www.debra.org (2023).

```